MedTrace Logo

Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function

NCT03874117 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2025-09-03

Study results available
· View outcomes & findings →

Summary

The study will determine the efficacy of twice weekly hemodialysis in patients with residual kidney function.

Conditions

  • Hemodialysis
  • Kidney Failure, Chronic

Interventions

OTHER

Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis

Twice weekly hemodialysis for 4 weeks, then thrice weekly hemodialysis for 4 weeks.

OTHER

Thrice Weekly Hemodialysis then Twice Weekly Hemodialysis

Thrice weekly hemodialysis for 4 weeks, then twice weekly hemodialysis for 4 weeks.

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Palo Alto Veterans Institute for Research

    lead OTHER

Principal Investigators

  • Tammy Sirich, MD · Stanford/VA Palo Alto Health Care System

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2024-09-01
Completion
2025-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03874117 on ClinicalTrials.gov